{
    "title": "CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8",
    "pmid": "23213055",
    "pmcid": "PMC3548984",
    "study_parameters": [
        {
            "Study Parameters ID": 1444933951,
            "Variant Annotation ID": 1444933926,
            "Study Type": "prospective",
            "Study Cases": 166.0,
            "Study Controls": 287.0,
            "Characteristics": "endpoint: event (disease recurrence, contralateral breast cancer, second non-breast cancer, or death); PM/PM vs EM/EM",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.04",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.45,
            "Confidence Interval Start": 1.05,
            "Confidence Interval Stop": 5.73,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": "1444933926"
        },
        {
            "Study Parameters ID": 1444933961,
            "Variant Annotation ID": 1444933959,
            "Study Type": "prospective",
            "Study Cases": 166.0,
            "Study Controls": 287.0,
            "Characteristics": "endpoint: event (disease recurrence, contralateral breast cancer, second non-breast cancer, or death); PM/IM and EM/PM vs EM/EM",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.07",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 1.67,
            "Confidence Interval Start": 0.95,
            "Confidence Interval Stop": 2.93,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": "1444933959"
        },
        {
            "Study Parameters ID": 1444933989,
            "Variant Annotation ID": 1444933987,
            "Study Type": "prospective",
            "Study Cases": 166.0,
            "Study Controls": 287.0,
            "Characteristics": "endpoint: event (disease recurrence, contralateral breast cancer, second non-breast cancer, or death); IM/IM and EM/IM vs EM/EM",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.6",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 1.23,
            "Confidence Interval Start": 0.58,
            "Confidence Interval Stop": 2.61,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": "1444933987"
        }
    ],
    "var_drug_ann": [],
    "var_pheno_ann": [
        {
            "Variant Annotation ID": 1444933926,
            "Variant/Haplotypes": "CYP2D6*1, CYP2D6*3, CYP2D6*4",
            "Gene": "CYP2D6",
            "Drug(s)": "tamoxifen",
            "PMID": 23213055,
            "Phenotype Category": "Efficacy",
            "Significance": "yes",
            "Notes": "Note: article did not report all genotypes; only *1/variant allele and homozygous variant allele but no combinations of variant alleles e.g. PM/IM even if phenotype grouping exist. Genotyped for null alleles [*3 (2549 del A),*4(1846G>A), and *6(1707T>del)] reduced alleles [*10 (100 C>T and 1846 G>A) and *41 (2988 G>A)] with Applied Biosystems Taqman assay; duplicated alleles could not be assayed. \"extensive\" metabolizers do not carry a null or reduced allele (EM/EM); those with 1 to 2 reduced alleles without a null allele (EM/IM, IM/IM); one null allele (PM/IM, PM/EM), and \"poor\" metabolizers, those with 2 null alleles (PM/PM). Post-menopausal women with estrogen receptor positive breast cancer were treated 5 years with tamoxifen only. The study grouped cases (cancer recurrence) and controls (no recurrence). In a second study arm (tamoxifen+ anastrozole) the higher risk did not persist after switching to anastrozole. [postmenopausal] [adjuvant] [DNA source: paraffin-embedded tissue] [HWE: yes for *4, *6, *10; no for *3, *41]",
            "Sentence": "CYP2D6 *3/*3 + *4/*4 are associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.",
            "Alleles": "*3/*3 + *4/*4",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "likelihood of",
            "Phenotype": "Efficacy:Recurrence",
            "Multiple phenotypes And/or": "and",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in women with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "*1/*1",
            "Comparison Metabolizer types": null,
            "PMID_norm": "23213055",
            "Variant Annotation ID_norm": "1444933926"
        },
        {
            "Variant Annotation ID": 1444933959,
            "Variant/Haplotypes": "CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*6",
            "Gene": "CYP2D6",
            "Drug(s)": "tamoxifen",
            "PMID": 23213055,
            "Phenotype Category": "Efficacy",
            "Significance": "no",
            "Notes": "Note: PM/IM genotypes are missing; article did not report all genotypes; only *1/variant allele and homozygous variant allele but no combinations of variant alleles e.g. PM/IM even if phenotype grouping exist.Genotyped for null alleles [*3 (2549 del A),*4(1846G>A), and *6(1707T>del)] reduced alleles [*10 (100 C>T and 1846 G>A) and *41 (2988 G>A)] with Applied Biosystems Taqman assay; duplicated alleles could not be assayed. \"extensive\" metabolizers do not carry a null or reduced allele (EM/EM); those with 1 to 2 reduced alleles without a null allele (EM/IM, IM/IM); one null allele (PM/IM, PM/EM), and \"poor\" metabolizers, those with 2 null alleles (PM/PM). Post-menopausal women with estrogen receptor positive breast cancer were treated 5 years with tamoxifen only. The study grouped cases (cancer recurrence) and controls (no recurrence). In a second study arm (tamoxifen+ anastrozole) the higher risk did not persist after switching to anastrozole. [postmenopausal] [adjuvant] [DNA source: paraffin-embedded tissue] [HWE: yes for *4, *6, *10; no for *3, *41]",
            "Sentence": "CYP2D6 *1/*3 + *1/*4 + *1/*6 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.",
            "Alleles": "*1/*3 + *1/*4 + *1/*6",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "likelihood of",
            "Phenotype": "Efficacy:Recurrence",
            "Multiple phenotypes And/or": "and",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in women with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "*1/*1",
            "Comparison Metabolizer types": null,
            "PMID_norm": "23213055",
            "Variant Annotation ID_norm": "1444933959"
        },
        {
            "Variant Annotation ID": 1444933987,
            "Variant/Haplotypes": "CYP2D6*1, CYP2D6*10, CYP2D6*41",
            "Gene": "CYP2D6",
            "Drug(s)": "tamoxifen",
            "PMID": 23213055,
            "Phenotype Category": "Efficacy",
            "Significance": "no",
            "Notes": "Genotyped for null alleles [*3 (2549 del A),*4(1846G>A), and *6(1707T>del)] reduced alleles [*10 (100 C>T and 1846 G>A) and *41 (2988 G>A)] with Applied Biosystems Taqman assay; duplicated alleles could not be assayed. \"extensive\" metabolizers do not carry a null or reduced allele (EM/EM); those with 1 to 2 reduced alleles without a null allele (EM/IM, IM/IM); one null allele (PM/IM, PM/EM), and \"poor\" metabolizers, those with 2 null alleles (PM/PM). Post-menopausal women with estrogen receptor positive breast cancer were treated 5 years with tamoxifen only. The study grouped cases (cancer recurrence) and controls (no recurrence). In a second study arm (tamoxifen+ anastrozole) the higher risk did not persist after switching to anastrozole. [postmenopausal] [adjuvant] [DNA source: paraffin-embedded tissue] [HWE: yes for *4, *6, *10; no for *3, *41]",
            "Sentence": "CYP2D6 *1/*10 + *1/*41 + *10/*10 + *41/*41 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.",
            "Alleles": "*1/*10 + *1/*41 + *10/*10 + *41/*41",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "likelihood of",
            "Phenotype": "Efficacy:Recurrence",
            "Multiple phenotypes And/or": "and",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in women with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "*1/*1",
            "Comparison Metabolizer types": null,
            "PMID_norm": "23213055",
            "Variant Annotation ID_norm": "1444933987"
        }
    ],
    "var_fa_ann": []
}